Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

BACKGROUND: In the phase III LUX-Head & Neck 1 (LUX-H&N1) trial, second-line afatinib significantly improved progression-free survival (PFS) versus methotrexate in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Here, we evaluated association of prespeci...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, E. E. W., Licitra, L. F., Burtness, B., Fayette, J., Gauler, T., Clement, P. M., Grau, J. J., del Campo, J. M., Mailliez, A., Haddad, R. I., Vermorken, J. B., Tahara, M., Guigay, J., Geoffrois, L., Merlano, M. C., Dupuis, N., Krämer, N., Cong, X. J., Gibson, N., Solca, F., Ehrnrooth, E., Machiels, J.-P. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834024/
https://www.ncbi.nlm.nih.gov/pubmed/28961833
http://dx.doi.org/10.1093/annonc/mdx344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834024/
https://www.ncbi.nlm.nih.gov/pubmed/28961833
http://dx.doi.org/10.1093/annonc/mdx344

Ejemplares similares